

Cerebrovascular Diseases in Cancer Patients

Ji-Yong Lee, M.D., Joon-Bum Kwon, M.D., Hyun-Duk Yang, M.D., Seong-Ik Lee, M.D.,
Bum-Gi Han, M.D., Joon-Shik Moon, M.D., Sung-Soo Lee, M.D.

Department of Neurology, Wonju Christian Hospital, Wonju College of Medicine, Yonsei University

Background : The association of vascular thrombosis with cancer has been known since Trousseau's description of venous thrombophlebitis in patients with carcinoma. Previous studies, mainly autopsy-based, have suggested that the stroke spectrum in cancer patients differ from that of the general population. However, no studies that address this question in the adult oncological population from a clinical perspective are available in Korea. We therefore assessed the clinical features of cerebrovascular diseases in cancer patients. **Methods :** We retrospectively analyzed 44 cases of symptomatic cerebrovascular disease in cancer patients who were admitted to the Wonju Christian Hospital from January 1993 to June 1998 by reviewing their charts and brain CT or MRI; primary cancer, the interval from a cancer diagnosis to the occurrence of stroke, the incidence of hypercoagulability as an infarction cause, the location and size of the infarction, the type of hemorrhage, and the prognosis. **Results :** The mean age was 62.3 years. Twenty eight cases (63.6%) were ischemic stroke and sixteen cases (36.4%) were hemorrhagic stroke. The most common primary cancer of infarction and hemorrhage was stomach cancer. In ischemic patients, the most common cell type of cancer was adenocarcinoma and six cases (21.4%) were considered to have hypercoagulability as a cause. In hemorrhagic patients, seventy percent of patients with coagulopathy died in the hospital or were discharged moribundly. **Conclusions :** Although hypercoagulability is present to a greater extent in the patient population than in the general population, it appears that conventional stroke risk factors account for the majority of cerebral ischemic events in the adult cancer population. Cancer patients with intracranial hemorrhage owing to coagulopathy reveal poor prognosis.

J Korean Neurol Assoc 17(6):792~796, 1999

Key Words : Cancer, Cerebrovascular disease, Hypercoagulability

(hypercoagulability)		가	
1865	Trousseau가		5
	, ¹⁻³	Graus ⁶	3426
30%			117
		(nonbacterial thrombotic endocarditis)	(intravascular
가		coagulation) 가 51.3%	
(encephalopathy)			Chaturvedi
			30.3%

Manuscript received March 31, 1999.

Accepted in final form June 28, 1999.

* Address for correspondence

Ji-Yong Lee, M.D.

Department of Neurology,

Wonju College of Medicine, Yonsei University

Ilsan-dong 162, Wonju, Kangwon-do, 220-701, Korea

Tel : +82-371-741-1252, Fax : +82-371-748-1752

E-mail : bstuff@wonju.yonsei.ac.kr

1. 1993 1 1998 6 5 6 2 140 mg/dl , 75 g
2 200 mg/dl 30 , 60 ,
90 1 200 mg/dl 가
6824 1
44 240 mg/dl 가 200 mg/dl 1

2. 44 , CT MRI 1.5 cm
(small infarction) (large infarction)
44
48
(CT)
(MRI)
가
가
1 1)
가 8가
2)
가 CT MRI
3 90 mmHg 140
mmHg

1. 44 가 22 , 가 6
28 (63.6%) 33
81 66.3 60 70
가 19 (67.9%)
10 (35.7%) 가
3 , , , , 2
(Table 1).
(adenocarcinoma) 15
(53.6%) 가 가
11 (39.3%)
1
가 24 (85.7%) ,
1 가 (Table 2).
6 (21.4%)
2
가 , prothrombin time (PT),
activated partial thromboplastin time (aPTT)
, D-dimer,
(FDP) 1가 9

Table 1. Primary Cancer

Primary Site	Infarction	Hemorrhage
Stomach	10(35.7%)	5(31.3%)
Liver	3(10.7%)	1(6.3%)
Lung	2(7.1%)	1(6.3%)
Kidney	2(7.1%)	
Bladder	2(7.1%)	
Lymphoma	2(7.1%)	
Leukemia		4(25.0%)
Colon and rectum	2(7.2%)	
Larynx	1(3.6%)	1(6.3%)
Thyroid		1(6.3%)
Esophagus	1(3.6%)	
Prostate		1(6.3%)
Cervix	1(3.6%)	1(6.3%)
Pancreas	1(3.6%)	
Unknown	1(3.6%)	1(6.3%)
Total	28(100%)	16(100%)

Table 2. Interval from time of cancer diagnosis to occurrence of stroke

	Infarction	Hemorrhage
Before cancer diagnosis	1(3.6%)	2(12.5%)
At time of cancer diagnosis	3(10.7%)	2(12.5%)
< 1 year	21(75.0%)	9(56.2%)
> 1 year	3(10.7%)	3(18.8%)
Total	28(100%)	16(100%)

Table 3. Location and size of infarction

	Anterior circulation	Posterior circulation	Total
Large infarction	14	6	20(71.4%)
Small infarction	7	1	8(28.6%)
Total	21(75.0%)	7(25.0%)	28(100%)

1 125×10³/μl, PT 11.6 sec (control 12.7 sec), aPTT 50.5sec (control 27.2 sec), 406.7mg/dl, D-dimer >0.5 μg/ml 1 190×10³/μl, PT 12.0sec (control 12.4 sec), aPTT 26.9sec (control 28.8 sec), 251mg/dl, FDP >40 μg/ml . 가 3 1 . 4 , 1 , 1 . 4 가 , 5 2 . 21 (75%), 7 (25%) 20 (71.4%), 8 (28.6%) 가 14 (50%) 가 (Table 3). 6 4 , 1 , 1 28 6 가 9 가 1 . 2. 16 가 7 , 가 9 54.2 50 가 6 (37.5%) . 13 (81.3%), 2 (12.5%), (6.2%) 1 (Table 4). 9 1 7 , 1 , 1 4 , 4 , 1 , 1 . 2 16 7 가 가 15% .⁹ 50%, 90% , 가

Table 4. Types of hemorrhage

Hemorrhage	Numbers of patient
Intracerebral hemorrhage	
Hypertensive	4(25.0%)
Secondary to coagulopathy	9(56.3%)
Subarachnoid hemorrhage	2(12.5%)
Subdural hematoma	1(6.2%)
Total	16(100%)

가 , 가, 가, PT aPTT .¹⁰⁻¹² 가 , .¹³ , procoagulant cytokine (extrinsic pathway) , thrombin, ADP . procoagulant tissue factor, cancer procoagulant, (mucin) . interleukin-1 tumor necrosis factor leukocyte adhesion molecule, platelet activating factor, tissue factor, plasminogen activator inhibitor 가 (vascular permeability factor) (microvascular permeability) 가 . 2,14-15 1 . 가 , 2 가 . Chaturvedi ⁷ , 가 . 가 가 , 가 , 가 CT MRI . Graus ⁶ 28.5% 가 , 14.5% 가

51.3% 가 .

Chaturvedi ⁷ (30.3%) (21.2%) 가

66.3

21.4% Chaturvedi ⁷ 가

Chaturvedi ⁷ 86% 가 73% 가 6

90% , 1,2,16

53.6%

가 ,¹⁷ 11

(39.3%) 가 가 가

가 1

24 (85.7%), 1

가

75%, 25%

71.4%, 28.6% , (50%)

6 5 2

4 가

Graus ⁶

가

10 62.5% 9

, 1

가 28 6 16 7

가 10 7

가

가 ,

가 가

가

가 ,

가

가 , PT, aPTT , FDP, D-dimer, fibrinopeptide A, antithrombin , protein C, protein S 가

가 ^{2,18} ,

가 1 44

가 21.4%

가

70%가

가

REFERENCES

1. Reagan TJ, Okazaki H. The thrombotic syndrome associated with carcinoma: A clinical and neuropathological study. *Arch Neurol*, 1974;31:390-395.
2. Sack GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiological and therapeutic features. *Medicine* 1977;56:1-37.
3. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. *Blood* 1983;62:14-31.
4. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. In: Schoenberg BS, ed. *Advances in Neurology*. vol 19. New York: Raven Press, 1978;579-592.
5. Rogers LR. Cerebrovascular complications in cancer patients. *Neurol Clin* 1991;9:889-899.
6. Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. *Medicine* 1985;64:16-35.
7. Chaturvedi S, Ansell J, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of

- hypercoagulability? *Stroke* 1994;25:1215-1218.
8. Dwen CA, Bowie EJW. Chronic intravascular coagulation syndromes. *Mayo Clin Proc* 1974;49:673-679.
 9. Goad KE, Gralnick HR. Coagulation disorders in cancer. *Hematol Oncol Clin North Am* 1996;10:457-484.
 10. Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. *Am J Clin Pathol* 1987;88:596-602.
 11. Luzzatto G, Schafer AI. The prethrombotic state in cancer. *Semin Oncol* 1990;17:147-159.
 12. Sun NC, McAfeen WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. *Am J Clin Pathol* 1979;71:10-16.
 13. Green KB, Silverstein RL. Hypercoagulability in cancer. *Hematol Oncol Clin North Am* 1996;10:499-530.
 14. Naschitz JE, Yeshurun D, Abramson J, et al. Ischemic heart disease precipitated by occult cancer. *Cancer* 1992;69:2712-2720.
 15. Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE. Occult cancer in patients with deep venous thrombosis. *Arch Intern Med* 1987;147:556-560.
 16. Amico L, Caplan LR, Thomas C. Cerebrovascular complications of mucinous cancers. *Neurology* 1989;39:522-526.
 17. , , . 1996;14:965-973.
 18. Nand S, Messmore H. Hemostasis in malignancy. *Am J Hematol* 1990;35:45-55.